Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)
Public ClinicalTrials.gov record NCT02542293. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC).
Study identification
- NCT ID
- NCT02542293
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 953 participants
Conditions and interventions
Conditions
Interventions
- Durvalumab +Tremelimumab Biological
- Gemcitabine + carboplatin Drug
- Gemcitabine + cisplatin Drug
- Paclitaxel + carboplatin Drug
- Pemetrexed + carboplatin Drug
- Pemetrexed + cisplatin Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years to 130 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2, 2015
- Primary completion
- Sep 20, 2020
- Completion
- Dec 30, 2026
- Last update posted
- Apr 30, 2026
2015 – 2026
United States locations
- U.S. sites
- 15
- U.S. states
- 8
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Anaheim | California | 92801 | — |
| Research Site | San Diego | California | 92123 | — |
| Research Site | Santa Rosa | California | 95403 | — |
| Research Site | Louisville | Kentucky | 40202 | — |
| Research Site | Florham Park | New Jersey | 07932 | — |
| Research Site | Albuquerque | New Mexico | 87102 | — |
| Research Site | East Setauket | New York | 11733 | — |
| Research Site | Fresh Meadows | New York | 11366 | — |
| Research Site | Poughkeepsie | New York | 12601 | — |
| Research Site | Stony Brook | New York | 11794 | — |
| Research Site | Canton | Ohio | 44710 | — |
| Research Site | Columbus | Ohio | 43219 | — |
| Research Site | Zanesville | Ohio | 43701 | — |
| Research Site | Pittsburgh | Pennsylvania | 15212 | — |
| Research Site | Houston | Texas | 77090 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 195 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02542293, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 30, 2026 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02542293 live on ClinicalTrials.gov.